Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Cancer Clinical Trial

Official title:

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06367959
• Other study ID #: 2021-0324
• Secondary ID: NCI-2024-02939
• Status: Recruiting
• Phase: N/A
• Start date: July 27, 2023
• Est. completion date: August 31, 2026

Study information

• Verified date: April 2024
• Source: M.D. Anderson Cancer Center
• Contact: Qian Lu, MD, PHD
• Phone: (713) 745-8324
• Email: qlu[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To learn more about participant experience as a Asian American immigrant breast cancer survivor and how writing about participant experiences may affect participant's health.

Description:

Primary Objective:

To determine the effects of writing therapy on QOL and perceived stress at the 6- and 12-month follow-ups.

Secondary Objective:

To discover the effects of writing therapy on stress biomarkers and perceived stress at the 3-month follow-up.

To explore the psychosocial and cultural mechanisms responsible for the benefits of writing therapy by using mixed methods.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 192
• Est. completion date: August 31, 2026
• Est. primary completion date: August 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (aged 18 and older) diagnosed with stage 0-III cancer (or acute leukemia in remission/ chronic myeloid leukemia in chronic phase).

• Self-identified as Asian, Asian Americans, any Asian or Asian American subgroup (Chinese, Vietnamese, Indian, Korean, etc.) ethnic/cultural background

• Completed primary treatment, including surgery, chemotherapy, and/or radiation therapy, immunotherapy, or targeted therapy within the preceding 5 years.

• Comfortable reading in English or in Chinese.

Exclusion Criteria:

• Inability to provide informed consent.

Related Conditions & MeSH terms

• Cancer

Intervention

Behavioral:
• Esays
Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.
• Questionnaires
Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later. Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay.

Locations

Country	Name	City	State
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Outcome Measure: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0		Time Frame: through study completion; an average of 1 year

External Links

•   MD Anderson Cancer Center Website